Compared with chemotherapy plus bevacizumab, the combination of atezolizumab with chemotherapy and bevacizumab provided longer OS (median, 19.5 vs. 14.7 months; HR; 0.80 95% CI 0.67–0.95) and PFS (median, 8.3 vs. 6.8 months; HR; 0.62 95% CI 0.52–0.74) in patients with EGFR/ALK wild-type NSCLC (42, 43). This evidence concerns the gene EGFR and non-small cell lung carcinoma.